Analysts Anticipate United Therapeutics Co. (NASDAQ:UTHR) to Announce $2.47 EPS
Wall Street brokerages forecast that United Therapeutics Co. (NASDAQ:UTHR) will post earnings of $2.47 per share for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for United Therapeutics’ earnings, with estimates ranging from $1.53 to $3.35. United Therapeutics posted earnings per share of $3.34 in the same quarter last year, which would suggest a negative year over year growth rate of 26%. The firm is scheduled to issue its next earnings results on Wednesday, February 26th.
According to Zacks, analysts expect that United Therapeutics will report full-year earnings of ($0.95) per share for the current fiscal year, with EPS estimates ranging from ($2.16) to ($0.21). For the next year, analysts anticipate that the business will post earnings of $10.64 per share, with EPS estimates ranging from $7.74 to $13.63. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that that provide coverage for United Therapeutics.
UTHR has been the topic of several recent analyst reports. Bank of America initiated coverage on shares of United Therapeutics in a report on Tuesday, December 3rd. They issued an “underperform” rating and a $80.00 target price on the stock. Credit Suisse Group raised their price target on United Therapeutics from $113.00 to $121.00 and gave the stock an “outperform” rating in a research note on Thursday. Zacks Investment Research lowered United Therapeutics from a “hold” rating to a “sell” rating and set a $93.00 price objective for the company. in a research report on Thursday, January 2nd. Wedbush reaffirmed a “buy” rating and issued a $237.00 price target on shares of United Therapeutics in a research report on Monday, February 3rd. Finally, JPMorgan Chase & Co. upgraded United Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $116.00 to $120.00 in a report on Friday, January 31st. Three analysts have rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $116.17.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Bank of America Corp DE raised its holdings in United Therapeutics by 75.3% during the fourth quarter. Bank of America Corp DE now owns 193,101 shares of the biotechnology company’s stock worth $17,008,000 after purchasing an additional 82,925 shares in the last quarter. Ellington Management Group LLC acquired a new stake in shares of United Therapeutics in the 4th quarter valued at $564,000. UBS Asset Management Americas Inc. lifted its stake in shares of United Therapeutics by 81.7% in the 4th quarter. UBS Asset Management Americas Inc. now owns 102,523 shares of the biotechnology company’s stock valued at $9,030,000 after purchasing an additional 46,100 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its position in United Therapeutics by 925.0% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 86,713 shares of the biotechnology company’s stock worth $7,638,000 after acquiring an additional 78,253 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in United Therapeutics during the 4th quarter worth $490,000. 93.26% of the stock is owned by institutional investors and hedge funds.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
Recommended Story: Book Value Per Share in Stock Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.